Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBITDA Margin of 647.95% for Q1 2026, up 3695.0% year-over-year from 17.07% in Q1 2025, and down 55.77% on a QoQ basis from 415.97% in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of EBITDA Margin data on file, last reported at 647.95% in Q1 2026.
- Quarterly EBITDA Margin rose 3695.0% year-over-year to 647.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 599.0% (up 55070.0% YoY) and the FY2025 annual result came in at 609.22%, up 28628.0% from the prior year.
- EBITDA Margin fell to 647.95% in Q1 2026 per NTLA's latest filing, from 415.97% in the prior quarter.
- Across five years, EBITDA Margin topped out at 6825.61% in Q4 2023 and bottomed at 2115.61% in Q2 2024.
- The 5-year median for EBITDA Margin is 780.13% (2023), against an average of 458.41%.
- The widest annual swing landed in 2022, when EBITDA Margin jumped 2308287 bps; it then plunged 784775 bps in 2024.
- Tracing NTLA's EBITDA Margin over 5 years: stood at 821.48% in 2022, then surged by 931 bps to 6825.61% in 2023, then sank by 115 bps to 1022.14% in 2024, then jumped by 59 bps to 415.97% in 2025, then slumped by 56 bps to 647.95% in 2026.
- Per Business Quant, the three latest NTLA EBITDA Margin figures stand at 647.95% (Q1 2026), 415.97% (Q4 2025), and 732.75% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -647.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -647.95% |
| Dec 31, 2025 | -415.97% |
| Sep 30, 2025 | -732.75% |
| Jun 30, 2025 | -713.65% |
| Mar 31, 2025 | -684.89% |
| Dec 31, 2024 | -1,022.14% |
| Sep 30, 2024 | -1,440.68% |
| Jun 30, 2024 | -2,115.61% |
| Mar 31, 2024 | -374.14% |
| Dec 31, 2023 | 6,825.61% |
| Sep 30, 2023 | -1,016.74% |
| Jun 30, 2023 | -918.57% |
| Mar 31, 2023 | -780.13% |
| Dec 31, 2022 | -821.48% |
| Sep 30, 2022 | -852.13% |
| Jun 30, 2022 | -728.23% |
| Mar 31, 2022 | -1,353.55% |
| Dec 31, 2021 | -651.12% |
| Sep 30, 2021 | -23,935.00% |
| Jun 30, 2021 | -1,050.49% |
| Mar 31, 2021 | -717.11% |
| Dec 31, 2020 | -640.21% |
| Sep 30, 2020 | -125.85% |
| Jun 30, 2020 | -200.52% |
| Mar 31, 2020 | -633.88% |
| Dec 31, 2019 | -259.24% |
| Sep 30, 2019 | -221.86% |
| Jun 30, 2019 | -229.24% |
| Mar 31, 2019 | -209.46% |
| Dec 31, 2018 | -242.31% |
| Sep 30, 2018 | -306.45% |
| Jun 30, 2018 | -289.42% |
| Mar 31, 2018 | -285.93% |
| Dec 31, 2017 | -370.65% |
| Sep 30, 2017 | -216.96% |
| Jun 30, 2017 | -270.69% |
| Mar 31, 2017 | -208.33% |
| Dec 31, 2016 | -192.32% |
| Sep 30, 2016 | -158.08% |
| Jun 30, 2016 | -165.15% |
| Mar 31, 2016 | -376.70% |
| Dec 31, 2015 | -324.34% |
| Sep 30, 2015 | -195.56% |
| Jun 30, 2015 | -248.51% |
| Mar 31, 2015 | -92.92% |